Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$15.3MFederal grants as PI21 awards
1Patents grantedLatest Nov 8, 2022
111Papers7,517 citations
Federal awards and patents by year
AwardsPatents
21 awards · $15.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 20, 2025 | NIH | SBIR Phase II Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples | $1.0M | Epicypher, Inc. |
| Sep 9, 2024 | NIH | SBIR Phase II Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples | $1.0M | Epicypher, Inc. |
| Jun 28, 2024 | NIH | SBIR Phase II Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells | $998K | Epicypher, Inc. |
| Jan 8, 2024 | NIH | SBIR Phase II Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | $185K | Epicypher, Inc. |
| Jan 5, 2024 | NIH | SBIR Phase II Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | $1.0M | Epicypher, Inc. |
| Jul 28, 2023 | NIH | SBIR Phase II Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells | $1.0M | Epicypher, Inc. |
| Jul 26, 2023 | NIH | SBIR Phase II Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | $96K | Epicypher, Inc. |
| Apr 10, 2023 | NIH | SBIR Phase II A new epigenetic toolbox for inflammation research and drug discovery | $1.0M | Epicypher, Inc. |
| Mar 27, 2023 | NIH | SBIR Phase II Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | $1.0M | Epicypher, Inc. |
| Aug 19, 2022 | NIH | SBIR Phase I High-resolution genomic mapping of ssDNA and associated proteins for Alzheimer's disease research | $500K | Epicypher, Inc. |
| Jul 26, 2022 | NIH | SBIR Phase II Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | $104K | Epicypher, Inc. |
| Apr 18, 2022 | NIH | SBIR Phase II A new epigenetic toolbox for inflammation research and drug discovery | $1.0M | Epicypher, Inc. |
| Jan 25, 2022 | NIH | SBIR Phase II Ultrasensitive multiomic platform using epitope-targeted DNA methylation mapping | $426K | Epicypher, Inc. |
| May 5, 2021 | NIH | SBIR Phase II A new epigenetic toolbox for inflammation research and drug discovery | $1.0M | Epicypher, Inc. |
| Nov 19, 2020 | NIH | SBIR Phase II Quantitative and highly versatile chromatin accessibility platform | $876K | Epicypher, Inc. |
| Aug 21, 2019 | NIH | SBIR Phase II A novel protein engineering tool for rapid manufacturing of designer nucleosomes | $985K | Epicypher, Inc. |
| May 13, 2019 | NIH | SBIR Phase II A nucleosome sliding assay platform to screen inhibitors of SWI/SNF chromatin remodeling complexes | $854K | Epicypher, Inc. |
| Sep 17, 2018 | NIH | SBIR Phase II A novel protein engineering tool for rapid manufacturing of designer nucleosomes | $1000K | Epicypher, Inc. |
| Jul 31, 2017 | NIH | SBIR Phase I Next-Generation Detection Reagents for Chromatin Immunoprecipitation | $225K | Epicypher, Inc. |
| May 22, 2017 | NIH | SBIR Phase I A nucleosome sliding assay platform to screen inhibitors of SWI/SNF chromatin remodeling complexes | $225K | Epicypher, Inc. |
| Nov 25, 2016 | NIH | SBIR Phase II Internally Calibrated Chromatin Immunoprecipitation Using Barcoded Nucleosomes | $663K | Epicypher, Inc. |
2 patents as inventor
- US 11493520Epicypher, Inc.Nov 8, 2022
- US Epicypher, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#16
Awards as PI#14
Patents#155
Companies
- Epicypher, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.